Etamsylate (n=165) | Control (n=169) | |
Known death or impairment or disability | 58/165 (35) | 57/169 (34) |
France | 33/90 (37) | 30/91 (33) |
Greece | 25/75 (33) | 27/78 (35) |
<29 completed weeks gestation at delivery | 18/31 (58) | 18/35 (51) |
=29 completed weeks gestation at delivery | 40/134 (29) | 39/134 (29) |
Inborn | 18/62 (29) | 25/73 (34) |
Outborn | 40/103 (39) | 32/96 (33) |
Age at entry | ||
<1 hour | 6/21 (29) | 10/23 (43) |
⩾1 hour | 51/143 (36) | 47/145 (32) |
Not known | 1/1 (100) | 0/1 (0) |
With cerebral scan abnormality at trial entry | 23/57 (40) | 30/61 (49) |
Without cerebral scan abnormality at trial entry | 35/108 (32) | 27/108 (25) |
Known death or severe impairment or disability | 47/165 (28) | 41/169 (24) |
France | 25/90 (28) | 19/91 (21) |
Greece | 22/75 (29) | 22/78 (28) |
<29 completed weeks gestation at delivery | 15/31 (48) | 17/35 (49) |
=29 completed weeks gestation at delivery | 32/134 (24) | 24/134 (18) |
Inborn | 15/62 (24) | 20/73 (27) |
Outborn | 32/103 (31) | 21/96 (22) |
Age at entry | ||
<1 hour | 5/21 (24) | 7/23 (30) |
⩾1 hour | 41/143 (29) | 34/145 (23) |
Not known | 1/1 (100) | 0/1 (0) |
With cerebral scan abnormality at trial entry | 20/57 (35) | 22/61 (36) |
Without cerebral scan abnormality at trial entry | 27/108 (25) | 19/108 (18) |
Values in parentheses are percentages.